Improved myocardial protection with nifedipine and potassium-based cardioplegia

Cardioplegia and myocardial ischemia during cardiopulmonary bypass

Presently myocardial protection can be obtained in three main ways: 1) energy conservation through chemical induction of rapid and complete diastolic arrest, 2) slowing of the metabolic rate and degradative process through the use of hypothermia, and 3) prevention or reversal of unfavourable ischemic-induced changes with various protective agents. These methods of myocardial protection and their effectiveness, the calcium metabolism during myocardial ischemia, and the effects of calcium channel blockers are briefly reviewed and discussed. It is stressed that myocardial protection during ischemic arrest is a complex entity, and that new modes of myocardial protection are needed in the future.

Effects of preoperative treatment with diltiazem on diastolic ventricular function after coronary artery bypass graft surgery

OBJECTIVE

To examine whether preoperative treatment with diltiazem could ameliorate left ventricular (LV) diastolic dysfunction in patients after coronary artery bypass graft (CABG) surgery.

DESIGN

Prospective, nonrandomized clinical study.

SETTING

University hospital.

PARTICIPANTS

Thirty-four patients with preserved LV function undergoing elective CABG surgery.

INTERVENTIONS

According to medical history, patients were divided into 2 groups: patients not receiving diltiazem (n = 17) and patients treated with once-daily oral diltiazem for at least 2 weeks (n = 17). All patients received preoperative beta-blockers.

MEASUREMENTS AND MAIN RESULTS

After induction of anesthesia, after sternal closure, and 4 hours after cardiopulmonary bypass (CPB), mitral and pulmonary venous flow velocities were measured with pulsed Doppler. LV short-axis end-diastolic area by Doppler transesophageal echocardiography (TEE) and hemodynamic variables were obtained simultaneously at comparable pulmonary capillary wedge pressures. Postoperatively, increased peak E and A velocities were observed in patients with diltiazem and controls and returned to baseline 4 hours post-CPB in controls. Changes in these velocities did not result in a decreased E/A ratio. Peak A velocity, E/A ratio, and E wave deceleration time were significantly dependent on heart rate, not peak E velocity. End-diastolic area at comparable pulmonary capillary wedge pressure remained unchanged. In relation to diltiazem, only peak A velocity and time velocity integral of the A wave (TVI-A) at 4 hours post-CPB differed from controls.

CONCLUSION

Diastolic function is preserved after CABG surgery and is not altered by diltiazem in patients with preserved LV systolic function. The persistence of increased peak A velocity and TVI-A into the postoperative period suggests improved atrial systolic function with diltiazem.

Preconditioning to improve myocardial protection

Major advances in the composition and delivery of cardioplegia have helped to reduce the morbidity and mortality associated with coronary bypass surgery. The discovery of the preconditioning response should facilitate the development of more powerful myocardial protective agents. These new agents may act to directly stimulate the preconditioning response or may act in a supplementary fashion to either augment the response or provide protection from alternate pathways. As new techniques of myocardial protection continue to be developed, the risk-to-benefit ratio of coronary bypass surgery will continue to improve. As a result of these improvements, surgeons will be able to offer surgery to an increasingly high risk patient population without increasing the morbidity or mortality currently associated with coronary bypass.

Effect of ATP and verapamil as cardioplegic additives in the isolated guinea pig heart

1. A comparative study on isolated guinea pig hearts was carried out to determine the effects of ATP and verapamil as cardioplegic additives. 2. The hearts were arrested by one of the plegic solutions: I, potassium 20 mmol/l; II, potassium 20 mmol/l+verapamil 1.1 mumol/l; III, potassium 20 mmol/l+ATP 10 mmol/l. After 45 min of hypothermic ischemia, the hearts were reperfused by Krebs-Henseleit buffer. 3. Postischemic percentage change of myocardial functions (heart rate, contractility, heart work) and tissue enzymes (LDH, SGOT, SGPT) were compared between the groups. 4. Although a rapid cardiac arrest could be obtained by verapamil added cardioplegia. Postischemic myocardial recovery was much better with ATP added cardioplegic solutions.

Blood cardioplegia: a review and comparison with crystalloid cardioplegia

The Oxford International Symposium on myocardial preservation provided an appropriate milestone and impetus to survey one aspect of operative myocardial preservation, namely blood cardioplegia, and to contrast it with the more popular crystalloid cardioplegia. This review is by no means complete or exhaustive but represents my best effort to summarize important information that has accumulated in the literature as blood cardioplegia, and our understanding of it, has evolved. It is appropriate to compare blood and crystalloid cardioplegia with respect to biochemical and physiological differences. Clinical comparison has been limited, for the most part, to randomized studies, and a number of differences and details of clinical management of the two techniques have been omitted, either because they seemed unimportant or there was no good information that would allow an objective comparison of their significance. Hopefully, the reader will recognize the intent to focus on meaningful differences and similarities between the two techniques and to present them fairly.

Effects of diltiazem on the functional recovery of the myocardium at organ and cellular level during prolonged hypothermic ischemic cardiac arrest

The effectiveness of diltiazem on the functional recovery of the heart, calcium (Ca++) uptake and binding, Ca++ ATPase of cardiac sarcoplasmic reticulum (SR), and MB fraction of creatine kinase (MBCK) of coronary sinus blood was investigated after one and a half hours of reperfusion following three hours of ischemic cardiac arrest. The dogs were divided into three groups: group I, sham bypass; group II, cold crystalloid cardioplegia; and group III, cold crystalloid cardioplegia with diltiazem. There was a decrease in aortic pressures left ventricular pressure development (dp/dt), left ventricular work index (LVWI), total systemic vascular resistance (TSVR), and left ventricular systolic pressure (LVSP) in the sham bypass group. There was a decrease in cardiac index (CI), LVWI, and mean right atrial pressure (mRAP) and an increase in TSVR and pulmonary vascular resistance (PVR) in group II as compared with group I. Although there was a tendency for a decrease in the indices of myocardial contractility in group II, they were not significantly different from those in group I. The indices of myocardial contractility, CI, and LVWI in group III were slightly higher than in group II, but they were not significantly different from each other. The values for calcium uptake by SR in groups II and III were similar but significantly lower than those in group I. Calcium binding in group III was significantly lower than that in group I. Calcium ATPase of SR in the three groups were similar. Although MBCK increased in all the groups, the increases were not significantly different among the three groups. The results of this study indicate that cold crystalloid cardioplegia with diltiazem was not better than cold crystalloid alone in preserving the cardiac contractility and cellular function during prolonged ischemic cardiac arrest. However, the cardiac function in terms of cardiac index was better preserved with diltiazem.

Clinical trial of nicardipine cardioplegia in pediatric cardiac surgery

To clarify the effectiveness of nicardipine, one of the dihydropyridine calcium-channel blockers, for myocardial protection during cold potassium cardioplegic arrest in pediatric cardiac surgery, a clinical trial of nicardipine (0.25 mg/L) added to potassium cardioplegic solution was performed in children undergoing surgical repair of congenital heart diseases. Twenty patients were selected to receive nicardipine cardioplegia and 13 patients received a standard potassium cardioplegia, serving as a control group. Nicardipine cardioplegia provided better cardiac performance in the early postoperative period and reduced release of the MB isozyme of creatine kinase, as determined during a 48-hour postoperative period. These results suggest that nicardipine added to cold potassium cardioplegic solution offers additional protection for the myocardium during ischemia and postischemic reperfusion in pediatric cardiac surgery.

Residual strain in rat left ventricle

Residual stress in an organ is defined as the stress that remains when all external loads are removed. Residual stress has generally been ignored in published papers on left ventricular wall stress. To take residual stress into account in the analysis of stress distributions in a beating heart, one must first measure the residual strain in the no-load state of the heart. Residual strains in equatorial cross-sectional rings (2-3 mm thick) of five potassium-arrested rat left ventricles were measured. The effects of friction and external loading were reduced by submersing the specimen in fluid, and a hypothermic, hyperkalemic arresting solution containing nifedipine and EGTA was used to delay the onset of ischemic contracture. Stainless steel microspheres (60-100 microns) were lightly imbedded on the surface of the slices, and the coordinates of the microspheres were digitized from photographs taken before and after a radial cut was made through the left ventricular free wall. Two-dimensional strains computed from the deformation of a slice after one radial cut were defined as the residual strains in that slice. It was found that the distributions of the principal residual stretch ratios were asymmetric with respect to the radial cut: in areas where substantial transmural strain gradients existed, the distributions of strain components were different on the two sides of the radial cut. A second radial cut produced deformations significantly smaller than those produced from the first radial cut. Hence, a slice with one radial cut may be considered stress free.(ABSTRACT TRUNCATED AT 250 WORDS)

Combination of calcium channel blocker and thrombolytic therapy in acute myocardial infarction

To evaluate the protective effect of nifedipine on ischemic myocardium, in addition to thrombolytic therapy, a total of 149 patients with acute myocardial infarction were included in a double-blind controlled study in which they received 20 mg sublingual nifedipine (74 patients in group 1) or placebo (75 patients in group 2) in the emergency ward, either intracoronary nifedipine, 0.2 mg before and 0.2 mg after reperfusion of the infarct-related vessel and 20 mg three times/day during the hospital stay, or placebo. Combined intravenous and intracoronary thrombolytic therapy was initiated by means of mechanical recanalization in nonreperfused vessels. There were no differences between group 1 and 2 with regard to age, sex, body weight, or location of infarct. Evolution of CK-MB release and cumulative CK-MB was higher in group 1 than in group 2. Changes with regard to regional and global left ventricular function and coronary anatomy were not significantly different (NS) between the two groups. Reocclusion occurred in 15 of 74 (20%) and 10 of 75 (13%) patients in groups 1 and 2, respectively. During the reperfusion period, second- and third-degree atrioventricular block occurred in 5.4% and 6.7% (NS), ventricular couplets in 17.6% and 24% (NS), ventricular tachycardia in 2.7% and 9.3%, and ventricular fibrillation in 2.7% and 8% of the patients, respectively. Mortality rates were 13% and 8%. The study demonstrates that even very early administration of nifedipine combined with intracoronary administration does not enhance the salvage of ischemic myocardium achieved by reperfusion.

Protection of the heart by nifedipine cardioplegia during coronary artery surgery. A clinical-haemodynamic evaluation

This study was undertaken to evaluate the myocardial preservation obtained by adding a Ca++ channel blocker, nifedipine, to cold potassium cardioplegia (4 mcg/Kg/L) in 24 patients undergoing coronary artery surgery. They were randomly divided into a treated (N) and a control (C) group. Significant differences between the two groups were noted in the cardiac arrest time (p less than 0.001), in the mechanical recovery mode (p less than 0.01) and in the inotropic support needed (p less than 0.01). Cardiac index increased significantly in group N but decreased in group C (p less than 0.01). Peripheral delta P/delta t and endocardial viability ratio (EVR) decreased in both groups. Coronary sinus and serum CK and CK-MB release were significantly lower in the treated group. ECG ischaemic changes occurred in 8 patients in group C but only in 1 case in group N (p less than 0.001). Arrhythmias occurred in 3 cases in group C (p less than 0.05). The incidence of perioperative myocardial infarction was not significant (2 cases in group C). These data suggest that nifedipine can protect the myocardial cell from ischaemic injury without depressing myocardial contractility or AV conduction.

In vitro plasma nifedipine concentration during heart-lung machine function

The use of calcium antagonists such as nifedipine for myocardial protection during cardiac surgery has been advocated by several authors. During extracorporeal circulation many factors, such as light, interaction with circuit materials and haematocrit, may contribute to decrease plasma clearance of calcium antagonists

In an in vitro model of a heart-lung machine, plasma nifedipine and prime concentrations were detected with a series of samples at different temperatures (25 °C and 37 °C), haematocrits (0%, 20%, 30% and 40%) and light conditions (light and dark).

The results show a rapid drop of nifedipine concentration with a halflife of about 3-9 minutes and this situation is influenced with statistical significance by the presence of light and increased haematocrit.

The knowledge of this condition is useful when nifedipine is used before/ during cardiopulmonary bypass and during cardioplegia and reperfusion infusion with the use of extracorporeal devices.

Normothermic blood cardioplegia reperfusion plus nifedipine after cardioplegic arrest: experimental study with a new delivery set

During the aortic crossclamping and the early period of reperfusion, the calcium metabolism plays an important role in myocardial ischaemic damage. In this study, we test the use of a calcium entry blocker (nifedipine) during the early reperfusion period after cardioplegic arrest. The experimental protocol was tested on 20 large white pigs weighing 28 ± 1 kg. All animals underwent hypothermic (28°C) cardiopulmonary bypass (CPB) and St Thomas II cold (4°C) cardioplegia was infused in a single dose (40 ml/kg of body weight) through the aortic root after aortic crossclamping (90 minutes). The animals were divided into four groups (five animals for each group): Group I-standard reperfusion after clamping the aorta; Group II-the same as Group I plus nifedipine 100 mg bolus in aortic root just prior to unclamping the aorta; Group III-reperfusion was done with warm (37°C) oxygenated blood cardioplegia via aortic root (flow rate 70 ml/min/100 gm of heart weight, St Thomas I I solution with haematocrit of 1 5% for five minutes); Group IV-the same as Group III, plus nifedipine in bolus (100 nmg) injected in aortic root prior to the cardioplegic blood reperfusion. In Groups III and IV reperfusion was performed with a new delivery set (Dideco D51 5) which allows cold crystallaoid cardioplegia to be poured into warm blood cardioplegia. Full thickness myocardial biopsies were taken before, during (90') and after (3', 5', 10' of reperfusion) the aortic crossclamping and the level of high energy phosphate (H EP) of ATP, CP, lactate and myocardial water content were measured. Global left ventricular function was evaluated measuring left atrial pressure (LAP) at constant cardiac output with a right heart preparation before cardioplegic arrest and after 30 minutes of reperfusion. The results show significant differences during reperfusion between the four groups as follows: (a) higher ATP recovery in Groups III and IV than in Groups I and II; (b) CP levels increased more significantly in Group IV than in the other groups; (c) lactate was lower in Groups I I I and IV; (d) myocardial water content increased significantly in Group I; (e) global left ventricular function showed that the heart of the animals of Groups III and IV could pump from 3-3.5 I/min. with a left atrial pressure of less than 20 mmHg in respect to the other two groups. We conclude that after prolonged aortic crossclamping, the reperfusion with warm oxygenated cardioplegic blood plus nifedipine provides better myocardial protection.

Calcium channel blockers and cardiac surgery

Calcium channel blockers have an important role in the pharmacotherapy of cardiovascular disorders. These agents act by inhibiting the slow inward current into excitable cells, exert direct negative inotropic, chronotropic, and dromotropic activity, and are potent vasodilators. These direct effects are modified by reflex autonomic stimulation and by pathologic states. Serious adverse effects of the calcium channel blockers are most frequently observed in patients with ventricular dysfunction, conduction system disease, or concomitant beta blockade. Calcium channel blockers are indicated in the treatment of angina pectoris, supraventricular arrhythmias, and hypertension. The use of these agents in patients with hypertrophic cardiomyopathy, congestive heart failure, and pulmonary hypertension is investigational. The calcium channel blockers are gaining increased importance in the management of patients undergoing cardiac surgery. Verapamil is indicated for the treatment of post-cardiac-surgical atrial flutter and fibrillation; however, the calcium antagonists are not effective as prophylaxis against postoperative supraventricular arrhythmias. Laboratory studies have shown that drug interactions exist between calcium channel blockers and inhalational anesthetics and nondepolarizing neuromuscular blocking agents; clinical studies have demonstrated that these interactions are rarely significant. Perioperative coronary spasm can be effectively treated with the calcium channel blockers. The timing of calcium antagonist withdrawal prior to surgery is controversial, but continuation of therapy until surgery is usually safe. The clinical significance of platelet function inhibition by the calcium antagonists is unknown. Protection of ischemic myocardium by calcium channel blockers has been demonstrated. Important interactions between the calcium antagonists, hypothermia, and the ionic constituents of cardioplegia require further study before the role of these agents as adjuncts to clinical cardioplegia is defined. Expanded indications and the introduction of new calcium channel blockers will result in increased use of these agents in the future.

The determinants of mortality and morbidity after multiple-valve operations

The factors predictive of hospital mortality and morbidity after contemporary multiple-valve surgical procedures were identified to develop strategies to improve the results of such procedures. Preoperative, intraoperative, and postoperative information was collected prospectively on 90 consecutive patients undergoing surgical procedures between 1982 and 1984. The operative mortality was 5.6%, and the incidence of postoperative low-output syndrome was 16.7%. Multivariate logistic regression analysis identified tricuspid regurgitation (p less than .03, improvement-of-fit chi square) and the aortic valve lesion (p less than .03) as the independent predictors of postoperative complications (mortality or low-output syndrome). Patients with tricuspid regurgitation and right ventricular decompensation and those with aortic stenosis and left ventricular hypertrophy had limited ventricular functional reserve and faced an increased risk. Improved methods of myocardial protection may reduce the risk in these patients.

Calcium-accentuated ischemic damage during reperfusion: the time course of the reperfusion injury in the isolated working rat heart model

The purpose of this study was to determine the time course of calcium-induced postischemic reperfusion injury to the myocardium, using an initial short-term calcium-enriched reperfusion solution. The isolated rat heart model was subjected to 30 min of normothermic potassium cardioplegia-induced ischemic arrest. Control hearts received normal calcium Krebs-Henseliet buffer (KHB) reperfusion. Experimental hearts were challenged with 10 min of calcium-enriched (KHB) reperfusion starting at 0, 1, 2, 5, 15, and 30 min after the beginning of reperfusion. Aortic flow recovery 60 min after reperfusion was used to determine functional recovery. Control hearts recovered 82 +/- 3% of preischemic aortic flow. Hearts which received calcium challenge at 0 and 1 min after the start of reperfusion recovered 43 +/- 4 and 69 +/- 3% of preischemic aortic flow, respectively (P less than 0.01 and P less than 0.05, respectively). Hearts which received calcium challenge 2, 5, 15, and 30 min after reperfusion recovered 75 +/- 2, 80 +/- 2, 85 +/- 2, and 83 +/- 2% of preischemic aortic flow, respectively. Our results indicate that the postischemic myocardium is very susceptible to calcium-accentuated ischemic damage during the initial period of reperfusion. The postischemic heart, however, quickly recovers its ability to withstand a calcium challenge. Five minutes after the start of reperfusion the heart is not influenced by calcium challenge.

Cardioplegia and calcium antagonists: a review

During open-heart operations, periods occur during which the blood supply to the heart is stopped. Myocardial damage can be limited by cooling and induction of electromechanical arrest (cardioplegia). Many animal studies and some clinical trials provide strong evidence for the use of calcium antagonists, such as nifedipine, verapamil hydrochloride, diltiazem hydrochloride, and lidoflazine, as adjuncts to cardioplegia to optimize the protection. Salutary effects of calcium antagonists are discussed in regard to possible mechanism of action, application time, and efficacy during hypothermia. A major conclusion is that virtually no negative effects on cardiac protection have as yet been described in experimental or clinical studies, apart from short-term negative inotropic responses, while there is an increasing body of positive evidence for their efficacy. A new development is the use of these drugs for regional cardioplegia during dilation of coronary arteries (transluminal angioplasty).

Terminal magnesium cardioplegia: protective effect in the isolated rat heart model using calcium accentuated ischemic damage

We have developed a modified isolated working rat heart model to study the effect of potassium and magnesium cardioplegia given just prior to reperfusion, "terminal cardioplegia," on preservation of aortic flow following a standard ischemic insult. The model incorporates a short-term calcium challenge at the beginning of reperfusion to accentuate ischemic injury. All hearts were given initial potassium cardioplegia and subjected to 30 min of normothermic ischemia. Terminal cardioplegia was given for the 2 min prior to reperfusion. Calcium-challenged hearts were reperfused initially with calcium-enriched reperfusate and then switched to standard reperfusate. Aortic flow prior to and 60 min after ischemia was used to determine functional protection. Hearts recovered 82 +/- 3% of preischemic aortic flow when reperfused with normocalcemic reperfusate. When the initial reperfusate was enriched with calcium, aortic flow was only 43 +/- 4% of control. Hearts given terminal magnesium cardioplegia and then challenged with calcium-enriched reperfusate recovered 79 +/- 4% of control aortic flow. Hearts given terminal potassium cardioplegia recovered only 53 +/- 5% of control aortic flow when challenged with calcium-enriched initial reperfusate. Our results indicate that the recovery of aortic flow is significantly reduced by short-term postischemic calcium challenge. This damage is blocked by terminal magnesium cardioplegia, but not by terminal potassium cardioplegia.

Effect of nifedipine in hypothermic cardioplegia: a phosphorus-31 nuclear magnetic resonance study

The ability of nifedipine to enhance myocardial protection was assessed on isolated perfused rat hearts subjected to 180 min of hypothermic (20 degrees C), global ischemia, followed by 45 min of normothermic reperfusion. Intracellular pH, ATP, Pi and phosphocreatine content were serially measured at 4 min intervals by phosphorus-31 nuclear magnetic resonance spectroscopy and correlated with simultaneously recorded hemodynamic parameters. Addition of nifedipine (0.075 mumol/l and 0.5 mumol/l) to Saint Thomas' cardioplegic solution reduced Pi accumulation during ischemic arrest and increased phosphocreatine levels during reperfusion. Post-ischemic functional recovery was not improved at a drug concentration of 0.075 mumol/l and was depressed at 0.5 mumol/l. These results clearly show that the presence of nifedipine in Saint Thomas' cardioplegic solution does not provide significant additional myocardial protection under hypothermic conditions.

Verapamil potassium cardioplegia and cardiac conduction

This clinical study analyzes the effect of potassium cardioplegic solution containing verapamil hydrochloride (1 mg/L) on cardiac conduction after release of the aortic cross-clamp and throughout recovery. Fifty consecutive patients undergoing open-heart operation were studied as a unit for postoperative conduction abnormalities. They were also analyzed in groups based on spontaneous ventricular conversion to regular rhythm (54%) and the need for single DC cardioversion (32%), or multiple DC cardioversions (14%). Results showed that spontaneous ventricular conversion had no relationship to aortic cross-clamp time and that DC cardioversion using 10 Ws had no detrimental effects on the myocardium or incidence of conduction abnormalities. The need for transient intraoperative pacing was lowest with spontaneous ventricular conversion, but not statistically different from single or multiple DC cardioversions. Only 3 patients (6%) required pacing in the intensive care unit. The incidence of postoperative atrial and ventricular arrhythmias was similar in all groups, and no deaths or episodes of malignant ventricular arrhythmias occurred. This study concludes that verapamil potassium cardioplegia is associated with excellent myocardial protection and a high incidence of transient intraoperative dysfunction of the atrioventricular node (70%) but a low incidence of postoperative pacing. Benign postoperative arrhythmias occur, but at hospital discharge, few conduction abnormalities (10%) persist.

Use of nifedipine during cardiac surgery for improved myocardial protection

The combined results of extended clinical trials conducted in two centers following successful laboratory trials are evaluated. From a population of 4,777 patients who underwent open heart surgery, 205 high-risk patients were selected for study. One hundred seventy patients (3.6 percent) were given nifedipine in cardioplegic solution. The remaining 35 patients served as control subjects and were compared with 39 treated patients in the randomized subset of 74. One third of the patients underwent valve replacement, one quarter underwent coronary artery bypass, and 40 percent underwent combinations of valve replacement, coronary artery bypass, and other procedures. Characteristically, the third group had a 50 percent increase in end-diastolic volumes and low cardiac indexes (1.7 +/- 0.1 liters/minute/m2). Average cross-clamp time was 77 minutes. At one center, an extracellular hyperkalemic-type solution was used to deliver an average dose of 407 +/- 22 micrograms nifedipine per patient. At the other center, a low-sodium hyperkalemic solution was used, and the average nifedipine dose was 476 +/- 22 micrograms. Hemodynamic studies in the randomized subset demonstrated approximately a twofold improvement in the treated group in cardiac index, stroke volume, stroke work index, and pulmonary vascular resistance following cardiopulmonary bypass. The incidence of acute low cardiac output death was 4 percent versus 11 percent in the control group. Survival for all treated patients was 86 percent. It is concluded that the addition of nifedipine reduced the incidence of acute global cardiac failure in the immediate postoperative interval.

Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction

Calcium antagonists have become accepted agents for the attenuation of myocardial ischemia when it becomes manifest as angina pectoris. However, it is not known whether these agents can protect ischemic myocardium during the early evolution of an acute myocardial infarct. Calcium antagonists could potentially improve myocardial perfusion, by relieving coronary spasm or improving collateral blood flow, and reduce the energy demands of the ischemic myocardium either directly or by reducing heart rate or contractility. In some studies, calcium antagonists have decreased the rate of adenosine triphosphate depletion in ischemia and reduced functional or structural indexes of ischemic injury after relatively brief periods (up to 2 hours) of injury. We have assessed the ability of verapamil to protect severely ischemic myocardium in dogs with a 40-minute test period of circumflex occlusion followed by reperfusion. After 4 days of recovery, infarcts were sized by histologic methods. Untreated dogs had subendocardial infarcts (the more moderately ischemic subepicardial region being salvaged by reperfusion). Pretreatment with verapamil reduced the size of these subendocardial infarcts from 34 +/- 8 to 8 +/- 3% of the ischemic circumflex vascular bed (anatomic area at risk). Thus, verapamil prevented cell death in a substantial proportion of the severely ischemic subendocardial region that otherwise would have died as a result of the 40-minute test period of ischemia. To establish whether verapamil could prevent cell death for a longer period of time in the less severely ischemic subepicardial region, a 3-hour period of coronary occlusion with reperfusion was studied.

Calcium antagonists--drug interactions

Evaluations of drug interactions should be done with caution. One needs to be aware of the reported interactions and apply the information on an individual basis. This review may therefore serve as a guide to the more common drug interactions and when drug therapy should be monitored closely in clinical practice. Major drug interactions with calcium antagonists are summarized in Table 2.

Calcium channel blockers: an intraoperative and postoperative trial in women

This study analyzes the effects of intraoperative and postoperative calcium channel blockers on myocardial protection, postoperative arrhythmias, perioperative infarctions, and survival. Thirty-nine women undergoing consecutive coronary artery bypass operations were placed either in a control group (N = 23), in which standard cold potassium cardioplegia was used, or in a verapamil-nifedipine group (N = 16), in which verapamil (1 mg per liter) was added to the standard cardioplegic solution and nifedipine was instituted postoperatively. The verapamil-nifedipine group showed a significant reduction in postoperative levels of creatine phosphokinase (p less than 0.05). Levels of aspartate aminotransferase were also reduced (74 IU/L) compared with those for the control group (114 IU/L). In the control group, there were 3 early deaths secondary to abrupt ventricular fibrillation, but no patient in the verapamil-nifedipine group died or had serious early ventricular arrhythmias. Late hemodynamic variables were similar in both groups. We conclude that calcium channel blockers enhance myocardial protection during ischemic arrest and may diminish the incidence of fatal early postoperative ventricular arrhythmias in women undergoing coronary revascularization.

Nifedipine cardioplegia experience: results of a 3-year cooperative clinical study

Previous animal studies and a preliminary clinical trial of the addition of nifedipine to cardioplegic solution demonstrated salutary effects in terms of postischemic performance. This report examines the combined results of extended clinical trials conducted in two centers: Barnes Hospital, St. Louis, and Allegheny General Hospital, Pittsburgh. From an open-heart population of 4,777 patients, 205 highest-risk persons were selected for study. One hundred seventy of them were given nifedipine in cardioplegic solution. The remaining 35 served as controls to compare with 39 treated patients in the randomized subset of 74. Thirty-eight percent were women; the average age was 61 +/- 1 year; and most were in New York Heart Association Class IV. One-third had valve replacement, one-quarter had coronary artery bypass grafting (CABG), and 37% had valve, CABG, and other procedures in combination. Characteristically, these patients had a 50% increase in end-diastolic volumes, low cardiac indexes (1.7 +/- 1 L/min/m2), and low left ventricular stroke work indexes (22 +/- 2 gm-m/m2). Average cross-clamp time was 77 minutes. At Allegheny, an extracellular hyperkalemic solution was used to deliver an average dose of 407 +/- 22 micrograms per patient. At Barnes, a low-sodium hyperkalemic solution was used; the average dose was 476 +/- 22 micrograms. The results of hemodynamic studies in the randomized subset demonstrated approximately a twofold greater improvement in the treated group in cardiac index, stroke volume, left ventricular stroke work index, and pulmonary vascular resistance immediately after bypass. The incidence of acute low cardiac output death was 4% versus 11% in the nontreated group. The hospital survivorship for all treated patients was 84%. It is concluded that the addition of a calcium antagonist, nifedipine, reduced the incidence of acute global cardiac failure in the immediate postoperative interval.

Correction of intraoperative diastolic myocardial dysfunction with nifedipine

We report the case of a 62-year-old man with severe aortic stenosis and hypertrophic cardiomyopathy, who could not be weaned from cardiopulmonary bypass after aortic valve replacement until buccal administration of the calcium-blocking agent nifedipine led to achievement of adequate hemodynamics. These observations demonstrate the importance of diastolic dysfunction in patients with hypertrophic cardiomyopathy, and suggest an important peri- and intraoperative role for calcium-blocking agents in their management. Recent hemodynamic studies have shown the importance of diastolic myocardial dysfunction in patients with hypertrophic cardiomyopathy, and demonstrated that calcium-blocking agents may enhance myocardial performance by reducing this dysfunction (Goodwin, 1982; Lorell et al., 1980, 1982; Sanderson et al., 1977). Although this new class of drugs has been increasingly used as an adjunct to cardioplegia, there is little information thus far on their application as treatment of intraoperative diastolic abnormalities. We report the case of a 62-year-old man with severe aortic stenosis and hypertrophic cardiomyopathy, who could not be weaned from cardiopulmonary bypass after aortic valve replacement until buccal administration of the calcium-blocking agent nifedipine led to an increase in cardiac output and blood pressure.

Synergistic effect of nifedipine and propranolol on adenosine (catabolite) release from ischemic rat heart

Both nifedipine a calcium antagonist, and propranolol a beta-adrenergic blocker, are used as protective agents of the ischemic myocardium. In the clinical setting, the combination of the two drugs is used successfully although several case reports indicate potential dangers of the combination. For this reason we decided to study the combined effect of nifedipine and DL-propranolol in the isolated rat heart made ischemic for a short period of time. Apex displacement was taken as a measure of contractility. Release of the AMP catabolites adenosine, inosine, (hypo)xanthine and uric acid was used as a marker of ATP breakdown. Contractility during ischemia was not affected by the drugs. DL-Propranolol (30 or 150 micrograms/l) had no effect on ischemic myocardial purine release, while nifedipine (15 micrograms/l) reduced purine release during ischemia by 33% (P less than 0.02). The combination of 15 micrograms/l nifedipine and 150 micrograms/l DL-propranolol decreased purine release by 53% (P less than 0.005 vs. nifedipine). We conclude from these results that propranolol has a synergistic effect, adding to the beneficial action of nifedipine on ischemic myocardium.

Calcium-channel blockade as an adjunct to heterogeneous delivery of cardioplegia

The clinical situation of heterogeneous cardioplegia was simulated in a canine model by temporary ligation of the circumflex coronary artery during a three-hour interval of cardioplegic arrest. Nifedipine and lidoflazine, administered prior to aortic clamping, were evaluated as adjuncts to cold (2 degrees C) crystalloid cardioplegia. Assessment was made of regional function (sonomicrometer systolic shortening) and of global function by measuring left atrial (LA) pressure at constant cardiac output (CO), aortic pressure, and heart rate, and by measuring stroke work at constant LA pressure, aortic pressure, and heart rate. Among 14 control dogs, only 7 could achieve a CO of 5 liters per minute following cardioplegic arrest. Left anterior descending coronary arterial systolic shortening recovered to only 86% of prearrest values (p less than 0.05), circumflex coronary arterial systolic shortening recovered only 28% (p less than 0.01), stroke work recovered 59% (p less than 0.01), and LA pressure was 6.7 mm Hg higher (p less than 0.01) than prior to cardioplegic arrest. Lidoflazine provided no statistically significant benefit in these animals (N = 4). However, dogs given nifedipine (N = 6) had very little change in left anterior descending coronary arterial systolic shortening (99% recovery), stroke work (93% recovery), and LA pressure (delta = 0.4 mm Hg). None of these changes was statistically significant. There was some deterioration in circumflex coronary arterial systolic shortening (56% recovery; p less than 0.05). All 6 dogs given nifedipine achieved a CO of 5 L/min following cardioplegic arrest. Clinical cardioplegia is typically heterogeneous cardioplegia. Calcium-channel blockade appears to be useful in this situation.

Fluorocarbon cardioplegia and myocardial protection

This study compares myocardial protection using nonoxygenated clear cardioplegia with oxygen-carrying solutions of blood (PO2, 100 mm Hg) and fluorocarbon (FC-47 perfluorotributylamine, PO2, 500 mm Hg), all containing 25 mEq/L of potassium chloride. Three groups of dogs, each consisting of 5 animals, were placed on cardiopulmonary bypass, and the aorta of each dog was cross-clamped for 45 minutes. Hemodynamic and biochemical variables were measured at baseline and during recovery. Levels of the myocardial isoenzyme of creatine phosphokinase (CPK-MB) in the coronary sinus were significantly lower in the fluorocarbon cardioplegia group at 15 minutes of aortic cross-clamping (p less than 0.01), while both the fluorocarbon and blood cardioplegia groups demonstrated lower CPK-MB levels at 45 minutes (p less than 0.001 and p less than 0.05, respectively), compared with the clear cardioplegia group. The blood and fluorocarbon groups had improved mean aortic blood pressure (p less than 0.02 and p less than 0.05, respectively) and left ventricular pressure. At 45 minutes of reperfusion and recovery, all hemodynamic and enzymatic variables were similar in each group. We conclude that oxygenated solutions better protect the myocardial cell, but that further work is needed to determine the most effective oxygen level for maximum protection with cardioplegia.

Determinants of operative survival following combined mitral valve replacement and coronary revascularization

To determine the operative survival rate following combined mitral valve replacement (MVR) and coronary artery bypass graft (CABG) operation, we evaluated 100 patients, who were seen consecutively at the Peter Bent Brigham and Brigham and Women's Hospital from 1972 to 1982. There were 63 men and 37 women; the mean age was 62 years. Thirty-six patients were in New York Heart Association (NYHA) Functional Class III, and 64 were in functional Class IV. Mitral regurgitation was predominant in 76 patients; mitral stenosis, in 24. Emergency operations were performed in 15 patients, and elective or semielective operations were performed in 85. There were 18 operative deaths (18%): 9 in patients having elective operations (10.5%) and 9 in those having emergency operations (60%; p less than 0.01). Significant preoperative factors related to operative death were NYHA functional class, increased pulmonary vascular resistance, lower cardiac index, and lower ejection fraction in the nonsurvivors. The rate of survival did not differ according to sex, age, or degree of coronary artery disease. In addition, myocardial protection with potassium cardioplegia and complete coronary revascularization significantly reduced operative mortality in the elective group of patients but did not alter the mortality in the emergency group.

Nifedipine reduces adenine nucleotide breakdown in ischemic rat heart

An ATP-sparing effect has been demonstrated for a number of calcium antagonists. Nifedipine probably has a similar action, but data supporting this view are limited. Therefore we decided to study the effect of nifedipine on high-energy phosphate (and carbohydrate) metabolism in the ischemic rat heart. Langendorff preparations were made ischemic for less than 15 min. The reduction in coronary flow was 60 or 70%. Apex displacement during ischemia, a measure of contractility, was comparable for nifedipine-treated and untreated hearts. Ischemia caused a considerable release of the AMP catabolites adenosine, inosine and (hypo)xanthine, and of lactate. Nifedipine (10-100 micrograms/l) prevented this in a dose-dependent way. The highest dose reduced the release of purines and lactate by 90% (P less than 0.01) and 60% (P less than 0.001), respectively. The drug acted in a similar way during reperfusion. Due to ischemia, the adenylate energy charge (ATP + 0.5 ADP)/(ATP + ADP + AMP), decreased 15% (P less than 0.001); nifedipine at a concentration of 100 micrograms/l prevented this decrease (P less than 0.05). We conclude that nifedipine exerts a beneficial effect on myocardial adenine nucleotide metabolism during ischemia and reperfusion.